MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (ATRC) (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold ...
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...
WEST CHESTER, Ohio., AtriCure, Inc., a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, announced today that the first patient was enrolled and ...
Clinical evidence demonstrates that AtriClip® devices exclude and electrically isolate the left atrial appendage AtriClip devices are the most widely implanted left atrial appendage management devices ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ANTONIO -- ...
Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery ...
Hosted on MSN
AtriCure targets $517M-$527M revenue in 2025 with strong growth in appendage management and pain management
CEO Michael Carrel highlighted that AtriCure achieved Q1 2025 revenue of $124 million, representing 14% growth compared to Q1 2024. This was driven by strong performance in pain management and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback